Lantern Pharma Inc. Announces Q2 2026 Results Release, Call

What Happened

• On August 14, 2026, Lantern Pharma Inc. filed a Form 8-K stating it will issue a press release announcing its financial results for the second quarter ended June 30, 2026. The company also said it will hold a conference call and live webinar the same day and will use a presentation to support its discussion. The press release is furnished as Exhibit 99.1 and the presentation as Exhibit 99.2 to the 8-K.

Key Details

• Filing date: August 14, 2026 (Form 8-K).
• Reporting period: Quarter ended June 30, 2026 (Q2 2026).
• Materials filed: Press release (Exhibit 99.1) and presentation for the conference call/webinar (Exhibit 99.2).
• The 8-K includes a Cover Page Interactive Data File (Inline XBRL) as noted in the exhibits.

Why It Matters

• This filing signals that Lantern Pharma will publicly disclose its Q2 2026 quarterly results and provide management commentary via a call/webinar — events that often contain revenue, earnings, cash position, and operational updates important to investors.
• The 8-K itself does not include financial figures; investors should review the Exhibits (press release and presentation) and listen to the company’s conference call/webinar for the detailed results and any forward-looking commentary.